Bill Gates and Vaccine Stocks

(To join our email list, click here.)
Breaking News

4 Coronavirus Vaccine Stocks the Bill & Melinda Gates Foundation Is Betting On

Pfizer

Bill Gates recently stated that he views Pfizer (NYSE:PFE) as the leader in the coronavirus vaccine race. In a CNBC interview, he said, “The only vaccine that, if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer.”

The Gates Foundation also owns shares of the big drugmaker. However, this investment wasn’t initiated because of Pfizer’s coronavirus program. Actually, the foundation first bought a stake in Pfizer back in 2002 with the stated intention of “expand[ing] access to the pharmaceutical company’s all-in-one injectable contraceptive, Sayana Press, giving women in the developing world an affordable option.” 

Gates is probably correct in assessing Pfizer as the coronavirus vaccine leader. The company expects to report initial results next month from a late-stage study of BNT162b2, the COVID-19 vaccine candidate that it’s developing with BioNTech (NASDAQ:BNTX). If all goes well, BNT162b2 could very well become the first coronavirus vaccine available to Americans. 

BioNTech

It’s not surprising that the Bill & Melinda Gates Foundation also owns shares of BioNTech. Again, though, the nonprofit foundation didn’t invest in the German biotech stock because of its coronavirus program. 

The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million. The foundation’s goal with this investment was to work with BioNTech to develop vaccines and immunotherapies for preventing HIV and tuberculosis (TB) infection.

BioNTech began developing its BNT162 COVID-19 vaccine program earlier this year. It had already made significant progress with this program when it announced a partnership with Pfizer in March.

CureVac

BioNTech wasn’t the first German biotech to attract the attention of the Gates Foundation. In 2015, the foundation committed to investing $52 million in CureVac (NASDAQ:CVAC). In addition, the Gates Foundation agreed to provide separate funding for several projects to develop vaccines based on CureVac’s messenger RNA (mRNA) platform. 

CureVac listed its shares on the Nasdaq stock exchange in August 2020. The company is currently evaluating its mRNA COVID-19 vaccine in early stage clinical studies.

Vir Biotechnology

The Gates Foundation was one of the lead investors in Vir Biotechnology (NASDAQ:VIR) at the biotech’s launch in late 2016 and early 2017. The foundation’s goal with its position in Vir was to “support the development of affordable and accessible HIV and TB prophylactic vaccine programs, and support the development of a new partner in the infectious disease space.”

Vir’s pipeline now includes several coronavirus-focused programs. The company recently began a phase 2/3 clinical study with its partner, GlaxoSmithKline, evaluating an antibody therapy targeting COVID-19. Vir expects to initiate a phase 2 study of another COVID-19 antibody therapy, VIR-7832, later this year. VIR-7832 could potentially be used to treat COVID-19 and as a vaccine to prevent infection. In addition, the biotech is conducting preclinical studies of an inhaled therapy targeting COVID-19. 

© 2007-2021 Walk In Verse All rights reserved

Share This

Share on facebook
Share on twitter
Share on telegram
Share on tumblr

Get News & Updates

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top